Literature DB >> 28666360

Overnight Closed-Loop Control Improves Glycemic Control in a Multicenter Study of Adults With Type 1 Diabetes.

Sue A Brown1, Marc D Breton1, Stacey M Anderson1, Laura Kollar1, Patrick Keith-Hynes2, Carol J Levy3, David W Lam3, Camilla Levister3, Nihat Baysal4, Yogish C Kudva5, Ananda Basu5, Vikash Dadlani5, Ling Hinshaw5, Shelly McCrady-Spitzer5, Daniela Bruttomesso6, Roberto Visentin7, Silvia Galasso6, Simone Del Favero7, Yenny Leal7, Federico Boscari6, Angelo Avogaro6, Claudio Cobelli7, Boris P Kovatchev1.   

Abstract

Context: Closed-loop control (CLC) for the management of type 1 diabetes (T1D) is a novel method for optimizing glucose control, and strategies for individualized implementation are being developed. Objective: To analyze glycemic control in an overnight CLC system designed to "reset" the patient to near-normal glycemic targets every morning. Design: Randomized, crossover, multicenter clinical trial. Participants: Forty-four subjects with T1D requiring insulin pump therapy. Intervention: Sensor-augmented pump therapy (SAP) at home vs 5 nights of CLC (active from 23:00 to 07:00) in a supervised outpatient setting (research house or hotel), with a substudy of 5 nights of CLC subsequently at home. Main Outcome Measure: The percentage of time spent in the target range (70 to 180 mg/dL measured using a continuous glucose monitor).
Results: Forty subjects (age, 45.5 ± 9.5 years; hemoglobin A1c, 7.4% ± 0.8%) completed the study. The time in the target range (70 to 180 mg/dL) significantly improved in CLC vs SAP over 24 hours (78.3% vs 71.4%; P = 0.003) and overnight (85.7% vs 67.6%; P < 0.001). The time spent in a hypoglycemic range (<70 mg/dL) decreased significantly in the CLC vs SAP group over 24 hours (2.5% vs 4.3%; P = 0.002) and overnight (0.9% vs 3.2%; P < 0.001). The mean glucose level at 07:00 was lower with CLC than with SAP (123.7 vs 145.3 mg/dL; P < 0.001). The substudy at home, involving 10 T1D subjects, showed similar trends with an increased time in target (70 to 180 mg/dL) overnight (75.2% vs 62.2%; P = 0.07) and decreased time spent in the hypoglycemic range (<70 mg/dL) overnight in CLC vs SAP (0.6% vs 3.7%; P = 0.03).
Conclusion: Overnight-only CLC increased the time in the target range over 24 hours and decreased the time in hypoglycemic range over 24 hours in a supervised outpatient setting. A pilot extension study at home showed a similar nonsignificant trend.
Copyright © 2017 Endocrine Society

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28666360      PMCID: PMC5630248          DOI: 10.1210/jc.2017-00556

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

1.  Statistical tools to analyze continuous glucose monitor data.

Authors:  William Clarke; Boris Kovatchev
Journal:  Diabetes Technol Ther       Date:  2009-06       Impact factor: 6.118

2.  Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.

Authors:  Kellee M Miller; Nicole C Foster; Roy W Beck; Richard M Bergenstal; Stephanie N DuBose; Linda A DiMeglio; David M Maahs; William V Tamborlane
Journal:  Diabetes Care       Date:  2015-06       Impact factor: 19.112

3.  2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.

Authors:  Jort Kropff; Simone Del Favero; Jerome Place; Chiara Toffanin; Roberto Visentin; Marco Monaro; Mirko Messori; Federico Di Palma; Giordano Lanzola; Anne Farret; Federico Boscari; Silvia Galasso; Paolo Magni; Angelo Avogaro; Patrick Keith-Hynes; Boris P Kovatchev; Daniela Bruttomesso; Claudio Cobelli; J Hans DeVries; Eric Renard; Lalo Magni
Journal:  Lancet Diabetes Endocrinol       Date:  2015-09-30       Impact factor: 32.069

4.  Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.

Authors:  John M Lachin; Saul Genuth; Patricia Cleary; Matthew D Davis; David M Nathan
Journal:  N Engl J Med       Date:  2000-02-10       Impact factor: 91.245

5.  Multinight "bedside" closed-loop control for patients with type 1 diabetes.

Authors:  Sue A Brown; Boris P Kovatchev; Marc D Breton; Stacey M Anderson; Patrick Keith-Hynes; Stephen D Patek; Boyi Jiang; Najib Ben Brahim; Paul Vereshchetin; Daniela Bruttomesso; Angelo Avogaro; Simone Del Favero; Federico Boscari; Silvia Galasso; Roberto Visentin; Marco Monaro; Claudio Cobelli
Journal:  Diabetes Technol Ther       Date:  2015-01-16       Impact factor: 6.118

6.  Modular closed-loop control of diabetes.

Authors:  S D Patek; L Magni; E Dassau; C Karvetski; C Toffanin; G De Nicolao; S Del Favero; M Breton; C Dalla Man; E Renard; H Zisser; F J Doyle; C Cobelli; B P Kovatchev
Journal:  IEEE Trans Biomed Eng       Date:  2012-04-03       Impact factor: 4.538

7.  Psychometric properties of the hypoglycemia fear survey-ii for adults with type 1 diabetes.

Authors:  Linda A Gonder-Frederick; Karen M Schmidt; Karen A Vajda; Megan L Greear; Harsimran Singh; Jaclyn A Shepard; Daniel J Cox
Journal:  Diabetes Care       Date:  2011-02-23       Impact factor: 19.112

8.  Effects of sleep restriction on glucose control and insulin secretion during diet-induced weight loss.

Authors:  Arlet V Nedeltcheva; Jacqueline G Imperial; Plamen D Penev
Journal:  Obesity (Silver Spring)       Date:  2012-04-19       Impact factor: 5.002

9.  Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study.

Authors:  Hood Thabit; Alexandra Lubina-Solomon; Marietta Stadler; Lalantha Leelarathna; Emma Walkinshaw; Andrew Pernet; Janet M Allen; Ahmed Iqbal; Pratik Choudhary; Kavita Kumareswaran; Marianna Nodale; Chloe Nisbet; Malgorzata E Wilinska; Katharine D Barnard; David B Dunger; Simon R Heller; Stephanie A Amiel; Mark L Evans; Roman Hovorka
Journal:  Lancet Diabetes Endocrinol       Date:  2014-06-16       Impact factor: 32.069

10.  Pilot studies of wearable outpatient artificial pancreas in type 1 diabetes.

Authors:  Claudio Cobelli; Eric Renard; Boris P Kovatchev; Patrick Keith-Hynes; Najib Ben Brahim; Jérôme Place; Simone Del Favero; Marc Breton; Anne Farret; Daniela Bruttomesso; Eyal Dassau; Howard Zisser; Francis J Doyle; Stephen D Patek; Angelo Avogaro
Journal:  Diabetes Care       Date:  2012-09       Impact factor: 19.112

View more
  7 in total

Review 1.  Keeping Up with the Diabetes Technology: 2016 Endocrine Society Guidelines of Insulin Pump Therapy and Continuous Glucose Monitor Management of Diabetes.

Authors:  Alfonso Galderisi; Elise Schlissel; Eda Cengiz
Journal:  Curr Diab Rep       Date:  2017-09-23       Impact factor: 4.810

2.  The UVA/Padova Type 1 Diabetes Simulator Goes From Single Meal to Single Day.

Authors:  Roberto Visentin; Enrique Campos-Náñez; Michele Schiavon; Dayu Lv; Martina Vettoretti; Marc Breton; Boris P Kovatchev; Chiara Dalla Man; Claudio Cobelli
Journal:  J Diabetes Sci Technol       Date:  2018-02-16

3.  Continuous Glucose Monitoring Efficacy in Routine Use.

Authors:  Tadej Battelino
Journal:  J Clin Endocrinol Metab       Date:  2018-06-01       Impact factor: 6.134

Review 4.  Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis.

Authors:  Eleni Bekiari; Konstantinos Kitsios; Hood Thabit; Martin Tauschmann; Eleni Athanasiadou; Thomas Karagiannis; Anna-Bettina Haidich; Roman Hovorka; Apostolos Tsapas
Journal:  BMJ       Date:  2018-04-18

Review 5.  Better TIR, HbA1c, and less hypoglycemia in closed-loop insulin system in patients with type 1 diabetes: a meta-analysis.

Authors:  Xiaojuan Jiao; Yunfeng Shen; Yifa Chen
Journal:  BMJ Open Diabetes Res Care       Date:  2022-04

6.  Transactions between Maternal and Child Depressive Symptoms Emerge Early in Life.

Authors:  Danielle S Roubinov; Elissa S Epel; Nancy E Adler; Barbara A Laraia; Nicole R Bush
Journal:  J Clin Child Adolesc Psychol       Date:  2019-08-27

Review 7.  Glycemic Status Assessment by the Latest Glucose Monitoring Technologies.

Authors:  Ilaria Malandrucco; Benedetta Russo; Fabiana Picconi; Marika Menduni; Simona Frontoni
Journal:  Int J Mol Sci       Date:  2020-11-03       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.